Molecular Characteristics of Early-Onset Colorectal Cancer According to Detailed Anatomical Locations: Comparison With Later-Onset Cases

Author:

Ugai Tomotaka12,Haruki Koichiro1,Harrison Tabitha A.3,Cao Yin45,Qu Conghui3,Chan Andrew T.6789,Campbell Peter T.10,Akimoto Naohiko1,Berndt Sonja11,Brenner Hermann121314,Buchanan Daniel D.151617,Chang-Claude Jenny1819,Fujiyoshi Kenji1,Gallinger Steven J.20,Gunter Marc J.21,Hidaka Akihisa3,Hoffmeister Michael12,Hsu Li3,Jenkins Mark A.22,Milne Roger L.222324,Moreno Victor25262728,Newcomb Polly A.329,Nishihara Reiko130,Pai Rish K.31,Sakoda Lori C.332,Slattery Martha L.33,Sun Wei3,Amitay Efrat L.12,Alwers Elizabeth12,Thibodeau Stephen N.34,Toland Amanda E.35,Van Guelpen Bethany3637,Woods Michael O.38,Zaidi Syed H.39,Potter John D.3,Giannakis Marios4041,Song Mingyang24530,Nowak Jonathan A.1,Phipps Amanda I.329,Peters Ulrike329,Ogino Shuji124142ORCID

Affiliation:

1. Program in MPE Molecular Pathological Epidemiology, Department of Pathology, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts, USA;

2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, Massachusetts, USA;

3. Public Health Sciences Division, Fred Hutchinson Cancer Center, Seattle, Washington, USA;

4. Division of Public Health Sciences, Department of Surgery, Washington University School of Medicine, St Louis, Missouri, USA;

5. Division of Gastroenterology, Department of Medicine, Washington University School of Medicine, St. Louis, Missouri, USA;

6. Clinical and Translational Epidemiology Unit, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts, USA;

7. Division of Gastroenterology, Massachusetts General Hospital, Boston, Massachusetts, USA;

8. Channing Division of Network Medicine, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts, USA;

9. Department of Immunology and Infectious Diseases, Harvard T.H. Chan School of Public Health, Boston, Massachusetts, USA;

10. Department of Epidemiology and Population Health, Albert Einstein College of Medicine, Bronx, New York, USA;

11. Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA;

12. Division of Clinical Epidemiology and Aging Research, German Cancer Research Center (DKFZ), Heidelberg, Germany;

13. Division of Preventive Oncology, German Cancer Research Center (DKFZ) and National Center for Tumor Diseases (NCT), Heidelberg, Germany;

14. German Cancer Consortium (DKTK), German Cancer Research Center (DKFZ), Heidelberg, Germany;

15. Colorectal Oncogenomics Group, Department of Clinical Pathology, The University of Melbourne, Parkville, Victoria, Australia;

16. University of Melbourne Centre for Cancer Research, Victorian Comprehensive Cancer Centre, Parkville, Victoria, Australia;

17. Genetic Medicine and Family Cancer Clinic, The Royal Melbourne Hospital, Parkville, Victoria, Australia;

18. Division of Cancer Epidemiology, German Cancer Research Center (DKFZ), Heidelberg, Germany;

19. University Medical Centre Hamburg-Eppendorf, University Cancer Centre Hamburg (UCCH), Hamburg, Germany;

20. Lunenfeld Tanenbaum Research Institute, Mount Sinai Hospital, University of Toronto, Toronto, Ontario, Canada;

21. Nutrition and Metabolism Section, International Agency for Research on Cancer, World Health Organization, Lyon, France;

22. Centre for Epidemiology and Biostatistics, Melbourne School of Population and Global Health, The University of Melbourne, Melbourne, Victoria, Australia;

23. Cancer Epidemiology Division, Cancer Council Victoria, Melbourne, Victoria, Australia;

24. Precision Medicine, School of Clinical Sciences at Monash Health, Monash University, Clayton, Victoria, Australia;

25. Oncology Data Analytics Program, Catalan Institute of Oncology (IDIBELL), L'Hospitalet de Llobregat, Barcelona, Spain;

26. CIBER de Epidemiología y Salud Pública (CIBERESP), Madrid, Spain;

27. Department of Clinical Sciences, Faculty of Medicine, University of Barcelona, Barcelona, Spain;

28. Colorectal Cancer Group, ONCOBELL Program, Bellvitge Biomedical Research Institute-IDIBELL, Hospitalet de Llobregat, Barcelona, Spain;

29. Department of Epidemiology, University of Washington, Seattle, Washington, USA;

30. Department of Nutrition, Harvard T.H. Chan School of Public Health, Boston, Massachusetts, USA;

31. Department of Laboratory Medicine and Pathology, Mayo Clinic Arizona, Scottsdale, Arizona, USA;

32. Division of Research, Kaiser Permanente Northern California, Oakland, California, USA;

33. Department of Internal Medicine, University of Utah, Salt Lake City, Utah, USA;

34. Division of Laboratory Genetics, Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota, USA;

35. Departments of Cancer Biology and Genetics and Internal Medicine, Comprehensive Cancer Center, The Ohio State University, Columbus, Ohio, USA;

36. Department of Radiation Sciences, Oncology Unit, Umeå University, Umeå, Sweden;

37. Wallenberg Centre for Molecular Medicine, Umeå University, Umeå, Sweden;

38. Memorial University of Newfoundland, Discipline of Genetics, St. John's, Canada;

39. Ontario Institute for Cancer Research, Toronto, Ontario, Canada;

40. Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA;

41. Broad Institute of MIT and Harvard, Cambridge, Massachusetts, USA;

42. Cancer Immunology and Cancer Epidemiology Programs, Dana-Farber Harvard Cancer Center, Boston, Massachusetts, USA.

Abstract

INTRODUCTION: Early-onset colorectal cancer diagnosed before the age of 50 years has been increasing. Likely reflecting the pathogenic role of the intestinal microbiome, which gradually changes across the entire colorectal length, the prevalence of certain tumor molecular characteristics gradually changes along colorectal subsites. Understanding how colorectal tumor molecular features differ by age and tumor location is important in personalized patient management. METHODS: Using 14,004 cases with colorectal cancer including 3,089 early-onset cases, we examined microsatellite instability (MSI), CpG island methylator phenotype (CIMP), and KRAS and BRAF mutations in carcinomas of the cecum, ascending colon, transverse colon, descending colon, sigmoid colon, and rectum and compared early-onset cases with later-onset cases. RESULTS: The proportions of MSI-high, CIMP-high, and BRAF-mutated early-onset tumors were lowest in the rectum (8.8%, 3.4%, and 3.5%, respectively) and highest in the ascending colon (46% MSI-high; 15% CIMP-high) or transverse colon (8.6% BRAF-mutated) (all P trend <0.001 across the rectum to ascending colon). Compared with later-onset tumors, early-onset tumors showed a higher prevalence of MSI-high status and a lower prevalence of CIMP-high status and BRAF mutations in most subsites. KRAS mutation prevalence was higher in the cecum compared with that in the other subsites in both early-onset and later-onset tumors (P < 0.001). Notably, later-onset MSI-high tumors showed a continuous decrease in KRAS mutation prevalence from the rectum (36%) to ascending colon (9%; P trend <0.001), followed by an increase in the cecum (14%), while early-onset MSI-high cancers showed no such trend. DISCUSSION: Our findings support biogeographical and pathogenic heterogeneity of colorectal carcinomas in different colorectal subsites and age groups.

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Gastroenterology,Hepatology

Cited by 6 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3